Therapeutic compounds
US10202360B2 · kind B2 · utility
1Cited by
3References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2017 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | Apr 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D515/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.